About: Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.46 (-2.67%)
IPSC NASDAQ Century Therapeutics Inc
Century Therapeutics Inc share price
Atividade de preço de IPSC
Último preço
$ 1,460
Variação (24h)
-0,04 USD (2,67%)
Volume
1.45M
Volume (média 4 sem.)
-
Abertura
$ 1,53
Variação do dia
$ 1,42 - $ 1,55
Fechamento anterior
$ 1,50
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
IPSC price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals